ÂÜÀòÂÒÂ×

David Ting has worked in the medical field since 2004. David began their career as an MGH Resident at Massachusetts General Hospital in 2004. In 2007, they became an Oncology Fellow at Dana Farber Cancer Institute. From 2008 to 2013, they were a Post-doctoral Research Fellow at Mass General Cancer Center, where they identified satellite non-coding RNAs in Cancer, characterized circulating tumor cells in gastrointestinal malignancies, and conducted next generation RNA-sequencing of solid malignancies. In 2010, they joined Harvard Medical School as an Associate Professor of Medicine, MD Faculty Advisor, and Assistant Professor. David also served as Subcommittee Head for MD Admissions for Harvard Medical School's Division of Health Sciences and Technology from 2012 to 2016. In 2016, they founded PanTher Therapeutics. In 2018, they joined Mass General Cancer Center as Co Director of the Biomarker Discovery Lab and Associate Clinical Director for Innovation. In 2019, they co-founded TellBio, Inc. and ROME Therapeutics.

David Ting completed their MD at Harvard Medical School from 1999 to 2004. Prior to that, they obtained a Bachelor of Science in Chemical Engineering and Biology from Massachusetts Institute of Technology between 1995 and 1999.